Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) is working with the Saccomanno Research Institute to advance Biomoda’s patented system for measuring the photon emission rate of CyPath®-stained cells to detect early-stage lung cancer.

Biomoda’s CyPath® labeling solution for the early detection of cancers is based on meso-tetra (4 carboxyphenyl) porphine or TCPP, a porphyrin compound that binds to cancer cells and fluoresces under specific frequencies of light. Participants in Biomoda’s pilot clinical study, which is nearing completion, provided deep-lung sputum samples to be labeled with the CyPath® solution and viewed under fluorescent microscopy. The samples are also screened for cancer with Pap stain analysis and CT scans. Pending FDA approval, CyPath® is for investigational use only.

“It is especially appropriate that Biomoda is working with the Saccomanno Research Institute since its namesake, the late Dr. Geno Saccomanno, pioneered the development of sputum cytology for the early detection of lung cancer,” said John Cousins, President of Biomoda. Working at St. Mary’s Hospital and Medical Center in Grand Junction, Colorado, Saccomanno originally focused on the prevalence of lung cancer in the uranium miners who lived in the area. He conducted nearly 50 years of research on the diagnostic applications of sputum cytology.

“Under the direction of Dr. Marty Jacobson, the Saccomanno Institute will provide expertise needed for the pivotal clinical study, which is the next step toward commercializing the CyPath® technology as a cancer screening tool appropriate for large populations,” Cousins said. “We are delighted that Dr. Jacobson’s laboratory has joined our pivotal study team.”

About Biomoda

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.

About the Saccomanno Research Institute

Building on the work begun by Dr. Geno Saccomanno, Ph.D., M.D., the Saccomanno Research Institute focuses on genetic, environmental and occupational diseases affecting the population served by the St. Mary’s Hospital medical community. As a result of its history with the health risks of uranium mining, the Institute has conducted epidemiological and clinical studies of the genetics of disease susceptibility, early detection of disease and disease outcomes.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 31, 2009. Forward-looking statements are made as of the date of this press release and are subject to change without notice.